MKMasahiro Kami

Masahiro Kami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masahiro Kami has a total of 173 co-authors. Here are the top co-authors by number of shared publications:

  • Yoichi Takaue

    Haematopoietic Stem Cell Transplantation Unit, the National Cancer Centre Hospital, Tokyo

    13 shared publications
  • H Hirai

    Department of Cell Therapy & Transplantation Medicine, University of Tokyo, Tokyo, Japan

    10 shared publications
  • Naoko Murashige

    Haematopoietic Stem Cell Transplant Unit, The National Cancer Centre Hospital

    9 shared publications
  • Y Kanda

    Department of Cell Therapy & Transplantation Medicine, University of Tokyo, Tokyo, Japan

    9 shared publications
  • Tamae Hamaki

    Department of Transfusion Medicine, Metropolitan Fuchu Hospital

    7 shared publications
  • Yukiko Kishi

    Haematopoietic Stem Cell Transplant Unit, The National Cancer Centre Hospital

    7 shared publications

Latest Publications

  • Guillain–Barre syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell transplantation

    by G Fujisaki, M Kami, N Murashige, Y Kishi, A Hori, A Chizuka, Y Ugawa, K Kobayashi, R Tanosaki


  • Open Access

    Graft failure following reduced‐intensity cord blood transplantation for adult patients

    by Hiroto Narimatsu, Masahiro Kami, Shigesaburo Miyakoshi, Naoko Murashige, Koichiro Yuji, Tamae Hamaki, Kazuhiro Masuoka, Eiji Kusumi, Yukiko Kishi, Tomoko Matsumura, et al.

    Summary: We reviewed the medical records of 123 adult reduced‐intensity cord blood transplantation (RI‐CBT) recipients to investigate the clinical features of graft failure after RI‐CBT. Nine (7·3%) had graft failure, and were classified as graft rejection rather than primary graft failure; they showed peripheral cytopenia with complete loss of donor‐type haematopoiesis, implying destruction of donor cells by immunological mechanisms rather than poor graft function. Three of them died of bacterial or fungal infection during neutropenia. Two recovered autologous haematopoiesis. The remaining four patients underwent a second RI‐CBT and developed severe regimen‐related toxicities. One died of pneumonia on day 8, and the other three achieved engraftment. Two of them died of transplant‐related mortality, and the other survived without disease progression for 9·0 months after the second RI‐CBT. In total, seven of the nine patients with graft failure died. The median survival of those with graft failure was 3·8 months (range, 0·9–15·4). Graft failure is a serious complication of RI‐CBT. As host T cells cannot completely be eliminated by reduced‐intensity preparative regimens, we need to be aware of the difficulty in differentiating graft rejection from other causes of graft failure following RI‐CBT. Further studies are warranted to establish optimal diagnostic and treatment strategies.


  • Open Access

    Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years

    by R Kojima, M Kami, Y Kanda, E Kusumi, Y Kishi, Y Tanaka, S Yoshioka, S Morishima, S Fujisawa, S-I Mori, et al.

    To evaluate the efficacy of reduced-intensity stem-cell transplantation (RIST), we retrospectively compared outcomes of 207 consecutive Japanese patients aged between 50 and 59 years with hematologic malignancies who received RIST (n=70) and conventional stem-cell transplantation (CST) (n=137). CST recipients received total body irradiation (TBI)-based or busulfan/cyclophosphamide-based regimens. RIST regimens were purine analog-based (n=67), 2 Gy TBI-based (n=2), and others (n=1). Most CST recipients (129/137) received calcineurin inhibitors and methotrexate as graft-versus-host (GVHD) prophylaxis, while 32 RIST recipients received cyclosporin. In all, 23 CST and five RIST recipients died without disease progression within 100 days of transplant. Grade II to IV acute GVHD occurred in 56 CST and 38 RIST recipients. There was no significant difference in overall survival (OS) and progression-free survival between CST and RIST. On multivariate analysis on OS, five variables were significant: preparative regimens (CST vs RIST) (hazard ratio=1.92, 95% confidence interval, 1.25–2.97; P=0.003), performance status (2–4 vs 0–1) (2.50, 1.51–4.16; PP=0.004), acute GVHD (2.57, 1.72–3.84; PP=0.002). We should be careful in interpreting results of this small-sized retrospective study; however, reduced regimen-related toxicity might contribute to better survival in RIST. The low relapse rates following RIST suggest a strong antitumor activity through allogeneic immunity.


  • Open Access

    Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer‐cell neoplasms

    by Naoko Murashige, Masahiro Kami, Yukiko Kishi, Sung‐Won Kim, Masami Takeuchi, Kosei Matsue, Yoshinobu Kanda, Makoto Hirokawa, Yoshinari Kawabata, Tomoko Matsumura, et al.

    Summary: The efficacy of allogeneic haematopoietic stem‐cell transplantation (allo‐HSCT) for natural killer (NK)‐cell neoplasms is unknown. We investigated the results of allo‐HSCT for NK‐cell neoplasms between 1990 and 2003 through questionnaires. After reclassification by a haematopathologist, of 345 patients who underwent allo‐HSCT for malignant lymphoma, 28 had NK‐cell neoplasms (World Health Organization classification): extranodal NK/T‐cell lymphoma (n = 22), blastic NK‐cell lymphoma (n = 3), and aggressive NK‐cell leukaemia (n = 3). Twelve were chemosensitive and 16 chemorefractory. Twenty‐two had matched‐related donors. Stem‐cell source was bone marrow in eight and mobilised peripheral blood in 20. Conditioning regimens were myeloablative (n = 23) and non‐myeloablative (n = 5). Grade 2–4 acute graft‐versus‐host disease (GVHD) and chronic GVHD developed in 12 and 8 respectively. Eight died of disease progression, three of infection, two of acute GVHD, one of veno‐occlusive disease, one of interstitial pneumonitis, and one of thrombotic microangiopathy. Two‐year progression‐free and overall survivals were 34% and 40% respectively (median follow‐up, 34 months). All patients who did not relapse/progress within 10 months achieved progression‐free survival (PFS) during the follow‐up. In multivariate analysis, stem cell source (BM versus peripheral blood; relative risk 3·03), age (≥40 years vs. versus others; relative risk 3·94) significantly affected PFS. Allo‐HSCT is a promising treatment for NK‐cell neoplasms.


  • Open Access

    Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation

    by H Narimatsu, M Kami, S Hara, T Matsumura, S Miyakoshi, E Kusumi, Y Kakugawa, Y Kishi, N Murashige, K Yuji, et al.

    Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospital between January 2002 and August 2004. TMA was diagnosed in seven patients based on intestinal biopsy (n=6) or autopsy results (n=1). While these patients showed some clinical symptoms such as diarrhea and/or abdominal pain, mental status alterations or neurological disorders were not observed in any of them. Laboratory results were mostly normal at the onset of TMA; >2% fragmented erythrocytes (n=1), 200 IU/dl lactic dehydrogenase (LD) (n=4). On endoscopic examination, TMA lesions, consisting of ulcers, erosions, and diffuse exfoliation, were distributed spottily from terminal ileum to rectum. Intestinal graft-versus-host disease (GVHD) and cytomegalovirus (CMV) colitis were confirmed in five and four patients, respectively. With therapeutic measures including supportive care (n=4), fresh frozen plasma (n=1), and a reduction of immunosuppressive agents (n=1), TMA improved in four patients. The present study demonstrates that intestinal TMA is a significant complication after RI-CBT. Since conventional diagnostic criteria can overlook TMA, its diagnosis requires careful examination of the gastrointestinal tract using endoscopy with biopsy.


  • Outcomes of patients with acute leukaemia who relapsed after reduced‐intensity stem cell transplantation from HLA‐identical or one antigen‐mismatched related donors

    by Kazuhiko Kobayashi, Masahiro Kami, Naoko Murashige, Eiji Kusumi, Yukiko Kishi, Tamae Hamaki, Akiko Hori, Tomoko Matsumura, Koichiro Yuji, Shigeru Masuo, et al.

    Summary: The characteristics of relapse following reduced‐intensity stem‐cell transplantation (RIST) remain to be clarified. We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine‐analogue‐based regimens. Their median age was 55 years (range, 29–65 years). Median interval between RIST and relapse was 4·9 months (range, 1·8–24·9 months). Three chose not to receive interventions. The remaining 16 patients received withdrawal of immunosuppression (n = 3), chemotherapy (n = 2), donor lymphocyte infusion (n = 10) and second transplantation (n = 7), alone (n = 9) or in combination (n = 7). Four are alive with a median follow‐up of 27·6 months (range, 16·0–28·9 months); three in remission and one in relapse. The 2‐year overall survival after relapse was 28·9%. Causes of death in 15 patients included progressive disease (n = 7), graft‐versus‐host disease (n = 5) and infections (n = 3). Cumulative incidences of relapse‐related and non‐relapse‐related deaths at 2 years after relapse were 37% and 32% respectively. Two prognostic factors were identified on univariate analysis: age [P = 0·017; hazard ratio (HR), 1·16; 95% confidence interval (CI), 1·03–1·32], and ALL as underlying disease (P = 0·011; HR, 10·4; 95% CI, 1·73–62·4). Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy‐based interventions; however they carry a significant risk of non‐relapse mortality.


  • Open Access

    Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan

    by E Kusumi, M Kami, Y Kanda, N Murashige, Y Kishi, R Suzuki, K Takeuchi, T E Tanimoto, T Mori, K Muta, et al.

    We conducted a nation-wide survey of 112 adult Japanese patients who underwent reduced-intensity stem cell transplantation (RIST) from 1999 to 2002. Underlying diseases included indolent (n=45), aggressive (n=58) and highly aggressive lymphomas (n=9). Median age of the patients was 49 years. A total of 40 patients (36%) had relapsed diseases after autologous stem cell transplantation and 36 patients (32%) had received radiotherapy. RIST regimens were fludarabine-based (n=95), low-dose total body irradiation-based (n=6) and others (n=11). Cumulative incidences of grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD were, respectively, 49 and 59%. Cumulative incidences of progression and progression-free mortality were 18 and 25%, respectively. With a median follow-up of 23.9 months, 3-year overall survival rates were 59%. A multivariate analysis identified three significant factors for progression, which are history of radiation (relative risk (RR) 3.45, confidential interval (CI) 1.12–10.0, P=0.03), central nervous system involvement (RR 6.25, CI 2.08–20.0, P=0.001) and development of GVHD (RR 0.28, CI 0.090–0.86, P=0.026). RIST may have decreased the rate of transplant-related mortality, and GVHD may have induced a graft-versus-lymphoma effect. However, whether or not these potential benefits can be directly translated into improved patient survival should be evaluated in further studies.


  • Open Access

    Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients

    by Y Kishi, N Murashige, M Kami, S Miyakoshi, Y Shibagaki, T Hamaki, Y Takaue, S Taniguchi, for the Tokyo Stem Cell Transplantation (SCT) Consortium

    Since the introduction of reduced-intensity stem-cell transplantation (RIST), allogeneic stem-cell transplantation has become available for elderly patients. While pharmacokinetics of cyclosporine might differ according to age or other factors, cyclosporine is uniformly started at an oral dose of 6 mg/kg/day. We retrospectively reviewed medical records of 35 patients aged between 32 and 65 (median 52) years who had undergone RIST. Doses of cyclosporine were adjusted to the target blood trough level of 150–250 ng/ml. Cyclosporine dosages were changed in 33 patients (94%). Dose reduction was required in 32 patients because of high blood levels (n=25), renal dysfunction (n=3), hepatic dysfunction (n=2), and hypertension (n=2). Cyclosporine doses were increased in one because of the suboptimal level. The median of the achieved stable doses was 3.1 mg/kg/day (range, 1.0–7.4). Five patients sustained Grade III toxicities according to NCI-CTC version 2.0: renal dysfunction (n=4), hyperbilirubinemia (n=2), and hypertension (n=2). No patients developed grade IV toxicity. There was no statistically significant difference in the frequency and severity of cyclosporine toxicities between patients aged 50 years and above and those below 50 years. The initial oral cyclosporine dose of 6 mg/kg/day was unnecessarily high irrespective of age. The possible overdose of cyclosporine might have aggravated regimen-related toxicities.


  • Reduced-Intensity Allogeneic Hematopoietic Stem-Cell Transplantation as an Immunotherapy for Metastatic Colorectal Cancer

    by Rie Kojima, Masahiro Kami, Akiko Hori, Naoko Murashige, Mutsuko Ohnishi, Sung-Won Kim, Tamae Hamaki, Yukiko Kishi, Yutaka Tsutsumi, Nobuo Masauzi, et al.

    Allogeneic stem-cell transplantation (allo-SCT) can induce curative graft-versus-leukemia reactions for hematologic malignancies through allogeneic immunity. Because the gastrointestinal tract is a target of graft-versus-host disease (GvHD), colorectal cancer might be a candidate for allo-SCT. Four patients with metastatic colorectal cancer underwent reduced-intensity stem-cell transplantation (RIST) in the National Cancer Center Hospital between July 2002 and February 2003. Three patients received transplants from an human leukocyte antigen (HLA)-identical related donor, and the remaining patient received selected CD34-positive cells from a two-loci HLA-mismatched donor. The basis of preparative regimen was busulfan 4 mg/kg for 2 days and fludarabine 25 mg/kg for 6 days. All the patients tolerated the preparative regimen and achieved engraftment without significant toxicities. All developed acute or chronic GvHD. Although serum levels of CA19–9 and carcinoembryonic antigen were transiently elevated after RIST in all the patients, the levels subsequently decreased below the levels from before RIST in all but one patient. Three had measurable lesions before RIST, one achieved partial response, and the others stable disease, which was durable for 120 and 60 days. Three patients died; the causes of death were progressive disease, GvHD, and accident. Postmortem examination was obtained for two patients; in one patient, the peritoneal metastatic lesions macroscopically disappeared, and in the other patient, the supraclavicular lymph node disappeared while the other measurable lesions remained stable. All the patients showed some evidence suggesting the presence of a graft-versus-tumor effect for colorectal cancer, which should be confirmed in a future prospective trial.